The Phase 3 clinical trial (NCT05957887) investigating dapagliflozin for its effects on left ventricular remodeling in patients with anterior STEMI reached primary completion on March 15, 2025. This milestone signifies the conclusion of data collection for the study's primary objectives.
Background
The study, titled "Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients," focuses on STEMI (ST-elevation myocardial infarction), a severe type of heart attack. Dapagliflozin is being evaluated for its potential role in mitigating cardiac remodeling post-event.
Trial design
The trial (NCT05957887) is a Phase 3 study designed to assess the impact of dapagliflozin. It enrolled 120 participants diagnosed with acute anterior STEMI who underwent early reperfusion. The study's methodology involves subdividing these patients into groups to evaluate the intervention.
What this means
The primary completion of this Phase 3 trial indicates that all data collection for the main objectives has concluded. Researchers will now proceed with data analysis to determine the short and intermediate term effects of dapagliflozin on left ventricular remodeling in anterior STEMI patients. The findings from this study could provide valuable insights into potential new therapeutic strategies for managing post-MI complications.
Source
Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public registry of clinical studies. The update for study NCT05957887 was posted on March 15, 2025, on clinicaltrials.gov.